针对HMGCS2:代抑制在T2DM并发症中加速NAFLD进展,而在并发T2DM中改善Cynaroside
Yongsheng Shu1, Wanqing Shen1, Wanyu Feng1
1Department of Pharmacology, School of Pharmacy, Wannan Medical College, Wuhu 241002, China.
Biomolecules
|August 28, 2025
概括
在2型糖尿病中,生成失调会恶化非酒精性脂肪性肝病 (NAFLD). 使用化增强化是一种治疗策略来治疗这种复杂的疾病.
科学领域:
- 肝病学
- 内分泌学
- 代谢疾病
背景情况:
- 同时的非酒精性脂肪肝 (NAFLD) 和2型糖尿病 (T2DM) 加快肝损伤,增加肝硬化和癌症的风险.
- 生成,即体的产生,在代谢调节中起作用,在T2DM相关的NAFLD中可能会发生改变.
研究的目的:
- 调查代在T2DM中介性NAFLD恶化中的作用.
- 阐明在非酒精性脂肪肝炎 (NASH) 复杂的T2DM中cynaroside的治疗机制.
主要方法:
- 在使用CDAHFD和链杆菌素的小鼠中确定NAFLD与T2DM模型.
- 通过腺病毒载体调节肝脏HMGCS2表达,用于过度表达或敲击.
- 通过口服给药,并分析肝脏病理,生成和衰老标志物.
主要成果:
- T2DM加速了NAFLD的进展,与失调的生成和肝脏HMGCS2表达有关.
- 在NASH- T2DM模型中,HMGCS2过度表达通过增强生成来减弱脂肪肝炎.
- 辛胺改善了肝损伤,减少了脂质积累,抑制了肝细胞衰老和SASP因子.
结论:
- 通过HMGCS2介导的基失调有助于T2DM中NAFLD的发病.
- 在NASH- T2DM中,cynaroside通过HMGCS2介导的生成产生治疗作用.
- 基调节是一种有前途的治疗策略,可以延缓T2DM-NAFLD的进展.
相关概念视频
Overview of Carbohydrate Metabolism
1.7K
Carbohydrate metabolism is a fundamental biochemical process that ensures a constant supply of energy to living cells. The most important carbohydrate is glucose, which can be broken down via glycolysis to enter into the Krebs cycle and eventually lead to the production of ATP through oxidative phosphorylation.
Glucose transport into cells is facilitated by a family of transport proteins called GLUT (Glucose Transporters). GLUT4 is the primary glucose transporter for insulin-stimulated glucose...
Glucose transport into cells is facilitated by a family of transport proteins called GLUT (Glucose Transporters). GLUT4 is the primary glucose transporter for insulin-stimulated glucose...
1.7K
Diabetes Mellitus: Type 2 and Gestational
2.9K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.9K
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
255
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
255
Oral Hypoglycemic Agents: Biguanides and Glitazones
288
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
288
Diabetes: Management and Pharmacotherapy
354
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
354
Oral Hypoglycemic Agents: Glinides
256
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
256


